FTC sues pharmaceuticals for illegally blocking generic versions of Opana ER, Lidoderm
MLex Summary: The US Federal Trade Commission filed a complaint alleging that Endo Pharmaceuticals and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost...To view the full article, register now.
Already a subscriber? Click here to view full article